PL EN


Preferences help
enabled [disable] Abstract
Number of results
2013 | 67 | 6 | 345–352
Article title

Ekspresja IL-1 i TNF- w mięśniakach macicy i tkance otaczającej u kobiet w różnym wieku

Content
Title variants
EN
Expression of IL-1 and TNF- in uterine myomas and myometrium in women of different age
Languages of publication
PL
Abstracts
EN
INTRODUCTION Fibroids are the most common benign tumors of the female reproductive organ. In uterine myoma cells, a disturbed expression of some cytokines and growth factors is found. AIM OF STUDY The aim of the study was to evaluate IL-1 and TNF-α expression in uterine myomas and myometrium in women of different age. MATERIAL AND METHODS The studies included 60 women. The control was a group of 20 patients in whom there were no fibroidal changes. The subjects were both in the reproductive and menopausal age. 20 women of childbearing age with fibroidal changes in the uterus (under age 45, FSH < 30 mIU/ml) and 20 women with fibroids at menopausal age (age 45–56, FSH > 30 mIU/ml) also qualified for the study. Immunohistochemical studies were performed on the sampled material. In the examined tissue fragments, the optical density of cells expressing IL-1 and TNF-α was evaluated, which reflects the concentration of the immunocytochemical reaction product. RESULTS Expression of the studied cytokines was higher in the myoma and surrounding myometrium comparing to the uterine myometrium of healthy women. CONCLUSIONS Increased expression of cytokines at the edge of uterine myomas may be a signal of the appearance of new tumors. Therefore, use of the expression levels of IL-1 and TNF-α as a prognostic factor should be considered.
PL
WSTĘP Mięśniaki macicy są najczęstszymi nowotworami o łagodnym charakterze żeńskiego narządu rodnego. W ich komórkach stwierdza się zaburzoną ekspresję niektórych cytokin i czynników wzrostu. CEL PRACY Celem badań była ocena ekspresji interleukiny-1 (IL-1) i czynnika martwicy nowotworu- (TNF-) w mięśniakach macicy kobiet w różnym wieku. MATERIAŁY I METODY W badaniach uczestniczyło 60 kobiet. Kontrolę czystą stanowiły pacjentki, u których nie stwierdzono zmian mięśniakowatych, zarówno w wieku reprodukcyjnym (10 kobiet), jak i okołomenopauzalnym (10 kobiet). Do badań zakwalifikowano 20 kobiet w wieku rozrodczym ze zmianami mięśniakowymi w macicy (poniżej 45 roku życia, FSH < 30 mIU/ml) oraz 20 kobiet z mięśniakami w wieku okołomenopauzalnym (45–56 rok życia, FSH > 30 mIU/ml). W badaniu immunohistochemicznym pobranych skrawków oceniono gęstość optyczną komórek z ekspresją IL-1 oraz TNF-α, która stanowi odzwierciedlenie stężenia produktu reakcji immunocytochemicznej. WYNIKI Ekspresja badanych cytokin w mięśniaku oraz otaczającym go miometrium w była wyższa niż w miometrium macicy kobiet zdrowych. WNIOSKI Zwiększona ekspresja cytokin na obrzeżu mięśniaków macicy może decydować o pojawieniu się nowych guzów, dlatego należy rozważyć wykorzystanie poziomu ekspresji IL-1 i TNF-α jako czynnika prognostycznego.
Discipline
Year
Volume
67
Issue
6
Pages
345–352
Physical description
References
  • 1. Ciarmela P., Islam M.S., Reis F.M. i wsp. Growth factors and myometrium: biological effects in uterine fibroid and possible clinical implications. Hum. Reprod. Update 2011; 17: 772–790.
  • 2. Reroń A., Huras H. Leczenie mięśniaków macicy. Ginekol. Pol. 2008; 3: 43–53.
  • 3. Wallach E., Vlahos F. Uterine myomas: An overview of development, clinical features, and management. Obstet. Gynecol. 2004; 104: 393–406.
  • 4. Duhan N., Sirohiwal D. Uterine myomas revisited. Eur. J. Obstet. Gynecol. Reprod. Biol. 2010; 152: 119–125.
  • 5. Parker W.H. Etiology, symptomatology and diagnosis of uterine myomas. Fertil Steril 2007; 87: 725–736.
  • 6. Cheng M.H., Wang P.H. Uterine myoma: a condition amenable to medical therapy? Exp. Opin. Emerg. Drugs 2008; 13: 119–133.
  • 7. Blok R., Łatkowski K.J., Blok K. Etiology and diagnostic problems in pregnant women with uterine myomas. Ginekol. Pol. 2002; 73: 266–270.
  • 8. Reroń A., Huras H. Etiopatogeneza mięśniaków macicy i ich wpływ na płodność i przebieg ciąży. Ginekol. Pol. 2008; 2: 49–57.
  • 9. Sozen I., Arici A. Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil. Steril. 2002; 78: 1–12.
  • 10. Sozen I., Arici A. Cellular biology of myomas: interaction of sex steroids with cytokines and growth factors. Obstet. Gynecol. Clin. North Am. 2006; 33: 41–58.
  • 11. Rothwarf D.M., Karin M. The NF-B activation pathway: a paradigm in information transfer from membrane to nucleus. Sci STKE 1999; 26: 12–16.
  • 12. Knop J., Wesche H., Lang D. i wsp. Effects of overexpression of IL-1 receptor-associated kinase on NF-B activation, IL-2 production and stress-activated protein kinases in the murine T cell line EL4. Eur. J. Immunol. 1998; 28: 3100–3109.
  • 13. Arici A. Sozen I. Expression, menstrual cycle-dependent activation, and bimodal mitogenic effect of transforming growth factor-1 in human myome-trium and leiomyoma. Am. J. Obstet. Gynecol. 2003; 188: 76–83.
  • 14. Arend W.P. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 2002; 13: 323–340.
  • 15. Terranova P.F., Hunter V.J., Roby K.F. i wsp. Tumor necrosis factor- in the female reproductive tract. Proc. Soc. Exp. Biol. Med. 1995; 209: 325–342.
  • 16. Marcinkiewicz J.L., Balchak S.K., Morrison L.J. The involvement of tumor necrosis factor- (TNF) as an intraovarian regulator of oocyte apoptosis in the neonatal rat. Front. Biosci. 2002; 7: 1997–2005.
  • 17. Kurachi O., Matsuo H., Samoto T., Maruo T. Tumor necrosis factor  expression in human uterine leiomyoma and its down-regulation by progesterone. J. Clin. Endocrinol. Metab. 2001; 86: 2275–2280.
  • 18. Maruo T., Laoag-Fernandez J.B., Takekida S. i wsp. Regulation of granulosa cell proliferation and apoptosis during follicular development. Gynecol. Endocrinol. 1999; 13: 410–419.
  • 19. Dinarello C.A. The biological properties of interleukin-1. Eur. Cytokine Netw. 1994; 5: 517–531.
  • 20. Dinarello C.A. Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 2009; 27: 519–550.
  • 21. Von Wolff M., Thaler C.J., Strowitzki T. i wsp. Regulated expression of cytokines in human endometrium through the menstrual cycle: dysregulation in habitual abortion. Mol. Hum. Reprod. 2000; 6: 627–634.
  • 22. Jasper M.J., Tremellen K.P., Robertson S.A. Reduced expression of IL-6 and IL-1 mRNAs in secretory phase endometrium of women with recurrent miscarriage. J. Reprod. Immunol. 2007; 73: 74–84.
  • 23. Kelly R.W., King A.E., Critchley H.O.D. Cytokine control in human endometrium. Reproduction 2001; 121: 3–19.
  • 24. King A.E., Collins F., Klonisch T. i wsp. An additive interaction be-tween the NF-B and estrogen receptor signaling pathways in human endometrial epithelial cells. Hum. Reprod. 2010; 25: 510–518.
  • 25. Inagaki N., Ung L., Otani T. i wsp. Uterine cavity matrix metallopro-teinases and cytokines in patients with leiomyoma, adenomyosis or endometria polyp. Eur. J. Obstet. Gynecol. Reprod. Biol. 2003; 111: 197–203.
  • 26. Tokyol C., Aktepe F., Dilek F.H. i wsp. Expression of cyclooxygenase-2 and matrix metalloproteinase-2 in adenomyosis and endometrial polyps and its correlation with angiogenesis. Int. J. Gynecol. Pathol. 2009; 28: 148–156.
  • 27. Kurachi O., Matsuo H., Samoto T. i wsp. Tumor necrosis factor  expression in human uterine leiomyoma and its down-regulation by progesterone. J. Clin. Endocrinol. Metab. 2001; 86: 2275–2280.
  • 28. Maruo T., Matsuo H., Shimomura Y. i wsp. Effects of progesterone on growth factor expression in human uterine leiomyoma. Steroids 2003; 68: 817–124.
  • 29. Pfeilschifter J., Koditz R., Pfohl M. i wsp. Changes in proinflammatory cytokine activity after menopause. Endocr. Rev. 2002; 23: 90–119.
  • 30. Ozmen B., Kirmaz C., Aydin K. i wsp. Influence of the selective oestro-gen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-, TGF-1 and bone turnover markers in the treatment of postmenopausal osteoporosis. Eur. Cytokine Netw. 2007; 18: 148–153.
  • 31. Sumitani H., Shozu M., Segawa T. i wsp. In situ estrogen synthesized by aromatase P450 in uterine leiomyoma cells promotes cell growth probably via an autocrine/intracrine mechanism. Endocrinology 2000; 141: 3852–3861.
  • 32. Swartz C.D., Afshari C.A., Yu L. i wsp. Estrogen-induced changes in IGF-I, Myb family and MAP kinase pathway genes in human uterine leiomyoma and normal uterine smooth muscle cell lines. Mol. Hum. Reprod. 2005; 11: 441–450.
  • 33. Shozu M., Murakami K., Inoue M. Aromatase and leiomyoma of the uterus. Semin. Reprod. Med. 2004; 22: 51–60.
  • 34. Bulun S.E., Imir G., Utsunomiya H. i wsp. Aromatase in endometriosis and uterine leiomyomata. J. Steroid Biochem. Mol. Biol. 2005; 95: 57–62.
  • 35. Imir A.G., Lin Z., Yin P. i wsp. Aromatase expression in uterine leiomyomata is regulated primarily by proximal promoters I.3/II. J. Clin. Endocrinol. Metab. 2007; 92: 1979–1982.
  • 36. Madej P., Plewka A., Plewka D. i wsp. The aromatase expression in myomas and myometriums of women in reproduction and perimenopausal age. Folia Histochem. Cytobiol. 2009; 47: 497–504.
  • 37. Plewka A., Madej P., Plewka D. i wsp. Immunohistochemical localization of selected pro-inflammatory factors in uterine myomas and myometrium in women of various ages. Folia Histochem. Cytobiol. 2013; 51: 73–83.
  • 38. Tetsuka T., Daphna-Iken D., Miller B.W. i wsp. Nitric oxide amplifies interleukin 1-induced cyclooxygenase-2 expression in rat mesangial cells. J. Clin. Invest. 1996; 97: 2051–2056.
  • 39. Morioka N., Inoue A., Hanada T. i wsp. Nitric oxide synergistically potentiates interleukin-1-induced increase of cyclooxygenase-2 mRNA levels, resulting in the facilitation of substance P release from primary afferent neurons: involvement of cGMP-independent mechanisms. Neuropharmacology 2002; 43: 868–876.
  • 40. Kamińska J., Kowalska M., Kotowicz B. i wsp. Cytokiny jako niezależne czynniki prognostyczne u chorych na nowotwory złośliwe. Współcz. Onkol. 2006; 10: 259–262.
  • 41. Kamińska J., Kowalska M., Kotowicz B. i wsp. Pretreatment serum levels of cytokines and cytokine receptors in patients with non-small cell lung cancer, and correlations with clinicopathological features and prognosis. M-CSF – an independent prognostic factor. Oncology 2006; 70: 115–125.
Document Type
article
Publication order reference
YADDA identifier
bwmeta1.element.psjd-46d34031-2439-4cec-a95f-85b7afc93791
Identifiers
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.